Potent, highly selective α2-adrenoceptor agonist (Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively). Displays greater selectivity over α1-adrenoceptors than clonidine and UK 14,304 (1620-, 220- and 300-fold respectively). Inhibits twitch response in electrically stimulated mouse vas deferens (pD2 = 9.0). Active in vivo; displays hypotensive, bradycardic, sedative, anxiolytic, hypothermic and analgesic effects.
Active Isomer also available.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 236.74. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.22 mL||21.12 mL||42.24 mL|
|5 mM||0.84 mL||4.22 mL||8.45 mL|
|10 mM||0.42 mL||2.11 mL||4.22 mL|
|50 mM||0.08 mL||0.42 mL||0.84 mL|
References are publications that support the biological activity of the product.
Savola et al (1986) Evidence for medetomidine as a selective and potent agonist at alpha 2-adrenoceptors. J.Aut.Pharmacol. 6 275 PMID: 2880852
Virtanen et al (1988) Characterization of the selectivity, specificity and potency of medetomidine as an α2-adrenoceptor agonist. Eur.J.Pharmacol. 150 9 PMID: 2900154
Scheinin et al (1989) Medetomidine - a novel α2-adrenoceptor agonist: a review of its pharmacodynamic effects. Prog.Neuro-Psychopharm.Biol.Psychiat. 13 635 PMID: 2571177
If you know of a relevant reference for Medetomidine hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Medetomidine hydrochloride, Medetomidine hydrochloride supplier, Potent, selective, α2-adrenoceptor, alpha2-adrenoceptor, a2-adrenoceptor, α2-Adrenergic, alpha2-Adrenergic, a2-adrenergic, agonists, Receptors, Adrenergic, Alpha-2, 5160, Tocris Bioscience
2 Citations for Medetomidine hydrochloride
Citations are publications that use Tocris products. Selected citations for Medetomidine hydrochloride include:
Furuta et al (2009) Role of alpha2-adrenoceptors and glutamate mechanisms in the external urethral sphincter continence reflex in rats. J.Urol. 181 1467 PMID: 19157445
Moura et al (2006) Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. Br J Pharmacol 149 1049 PMID: 17075569
Do you know of a great paper that uses Medetomidine hydrochloride from Tocris? Please let us know.
Reviews for Medetomidine hydrochloride
There are currently no reviews for this product. Be the first to review Medetomidine hydrochloride and earn rewards!
Have you used Medetomidine hydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.